TransCode Therapeutics to present TTX-MC138 Phase 1a trial data at ESMO 2026

RNAZ•2026-10-19

TransCode Therapeutics will present Phase 1a results for TTX-MC138 at the ESMO Congress in Madrid on October 23, 2026.

1. Trial presentation

The trial evaluates TTX-MC138 in patients with advanced solid tumors. The drug candidate targets miR-10b, a microRNA associated with metastatic progression.

TransCode Therapeutics to present TTX-MC138 Phase 1a trial data at ESMO 2026

1. Trial presentation

Related News

Tempus AI study shows pre-screening panel exceeds 80% sensitivity across 12 lung cancer biomarkers

Aon finds Canadian property and casualty market favors buyers entering 2027

FDA grants priority review to CorMedix's Rezzayo for fungal disease prevention

SciSparc shifts focus to agentic AI for cybersecurity and finance

Frontier Group Holdings publishes update to financial calendar